menu
    • menu
    [{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"FT-3171","moa":"USP-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Debiopharm"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FT-6876","moa":"CBP\/p300","graph1":"Oncology","graph2":"Preclinical","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"P-300","moa":"CREBBP\/EP300","graph1":"Oncology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novo Nordisk \/ Pathos","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Pathos"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by Novo Nordisk

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novo Nordisk

                            Denmark arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P-300

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Pathos

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor

                            Details : The license agreement aims to develop FT-7051 (renamed P-300), an oral, small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos’ first clinical-stage asset in its pipeline.

                            Product Name : P-300

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 23, 2023

                            Lead Product(s) : P-300

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Pathos

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novo Nordisk

                            Denmark arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FT-3171

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Debiopharm Extends Their DNA Damage Repair Footprint With New Oncology Pipeline Entry

                            Details : Debiopharm obtains global rights from Novo Nordisk for the development of FT-3171, a small molecule (ubiquitin-specific protease 1) USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway.

                            Product Name : FT-3171

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 03, 2023

                            Lead Product(s) : FT-3171

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pocenbrodib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Resear...

                            Details : FT-7051 is designed to attach to the CBP/p300 bromodomain potently and selectively, which then blocks androgen binding and reduces AR activation. In preclinical studies, FT-7501 demonstrated activity in both prostate cancer models that were sensitive.

                            Product Name : FT-7051

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 26, 2022

                            Lead Product(s) : Pocenbrodib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olutasidenib,Cytarabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Rigel Pharmaceuticals

                            Deal Size : $235.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH...

                            Details : Under the terms of the agreement, Rigel Pharmaceuticals will develop, manufacture and commercialize FT-2102 (olutasidenib), an oral, small molecule inhibitor of mIDH1 being investigated for the treatment of relapsed/refractory acute myeloid leukemia and ...

                            Product Name : FT-2102

                            Product Type : Other Small Molecule

                            Upfront Cash : $2.0 million

                            February 08, 2022

                            Lead Product(s) : Olutasidenib,Cytarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Rigel Pharmaceuticals

                            Deal Size : $235.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olutasidenib,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Rem...

                            Details : FT-2102 (Olutasidenib) in combination with Vidaza (Azacitidine) is found to be well-tolerated and, yielded durable complete remission in the first Phase 2 combination trial in patients with the mIDH1 form of acute myeloid leukemia.

                            Product Name : FT-2102

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 16, 2021

                            Lead Product(s) : Olutasidenib,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pocenbrodib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from ...

                            Details : FT-7051 is designed to attach to the CBP/p300 bromodomain potently and selectively, which then blocks androgen binding and reduces AR activation.

                            Product Name : FT-7051

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 10, 2021

                            Lead Product(s) : Pocenbrodib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olutasidenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021

                            Details : The Phase 1/2 study is a multicenter, open-label, multi-cohort evaluation of the safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of olutasidenib for patients with AML or myelodysplastic syndrome (MDS) with an IDH1 mutation.

                            Product Name : FT-2102

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 20, 2021

                            Lead Product(s) : Olutasidenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pocenbrodib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forma Dosed First Patient in Phase 1 Clinical Trial Evaluating FT-7051 Metastatic Castration-resistant Prostat...

                            Details : FT-7051 is a selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300) and a co-activator of androgen receptor. Phase 1 study includes late-line patients and patients with AR-v7 splice variants for whom there are no approved therapi...

                            Product Name : FT-7051

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 20, 2021

                            Lead Product(s) : Pocenbrodib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olutasidenib,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forma Therapeutics Announces Positive Top-Line Olutasidenib Data From A Planned Interim Analysis Of A Registra...

                            Details : FT2102-HEM-101 clinical trial data demonstrate a 30% CR and 3% CRh rate with olutasidenib monotherapy in 123 relapsed or refractory IDH1m AML patients.

                            Product Name : FT-2102

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 26, 2020

                            Lead Product(s) : Olutasidenib,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Forma Therapeutics

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olutasidenib,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forma Therapeutics Announces Clinical Data to be Presented at ASCO20 Virtual Scientific Program

                            Details : Oral presentation to highlight clinical data for olutasidenib, an investigational agent, in IDH1 mutant gliomas, including confirmation of blood-brain barrier penetration and preliminary disease control for patients with recurrent, predominantly enhanced...

                            Product Name : FT-2102

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 28, 2020

                            Lead Product(s) : Olutasidenib,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth